{"ModuleTitle": "Company Description", "CompanyName": "Novavax, Inc.", "Symbol": "NVAX", "Address": "21 FIRSTFIELD ROAD, GAITHERSBURG, Maryland, 20878, United States of America", "Phone": "240-268-2000", "Industry": "Biotechnology: Biological Products (No Diagnostic Substances)", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Novavax, Inc., together with our wholly-owned Swedish subsidiary, Novavax AB, is\r\na late-stage biotechnology company that promotes improved global health through\r\nthe discovery, development and commercialization of innovative vaccines to\r\nprevent serious infectious diseases. Using innovative proprietary recombinant\r\nnanoparticle vaccine technology, we produce vaccine candidates to efficiently\r\nand effectively respond to both known and emerging disease threats.\r\n\r\n \r\n\r\nWe were incorporated in 1987 under the laws of the State of Delaware. Our\r\nprincipal executive offices are located at 21 Firstfield Road, Gaithersburg,\r\nMaryland, 20878, and our telephone number is (240) 268-2000. Our common stock is\r\nlisted on the Nasdaq Global Select Market under the symbol \"NVAX.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f11%2f0001104659-20-031944.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Biegie Lee", "title": "Vice President-Information Technology"}, {"name": "Gale E. Smith", "title": "Chief Scientist, VP-Pre-Clinical Research"}, {"name": "Gregory M. Glenn", "title": "President-Research & Development"}, {"name": "John J. Trizzino", "title": "CFO, Treasurer, Chief Business Officer & Senior VP"}, {"name": "Stanley C. Erck", "title": "President, Chief Executive Officer & Director"}], "Number_of_employees": [], "Subsidiaries": ["NO INFO"]}